CELLCEUTIX, Inc. (NASDAQOTH:CTIX)

CAPS Rating: 1 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar SmartAce (99.90) Submitted: 4/20/2016 12:55:52 PM : Underperform Start Price: $1.64 CTIX Score: -13.66

After a coworker had finished his English lecture and his class had filed out, a tenth grader stayed ?behind to confront him.
“I don’t appreciate being singled out,” he told his teacher.
The teacher was confused. “What do you mean?”
“I don’t know what the ‘oxy’ part means, but I know what a ‘moron’ ?is, and you looked straight at me when you said it.”

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 4/4/2016 4:39:21 PM : Underperform Start Price: $1.58 CTIX Score: -16.30

How does Cellceutix keep its operations going? First, by spending hardly anything, and second via the drip drip of an ATM. Even so, cash was down to 6M as of the end of 2015, and I haven't seen any explanation from the company how they're planning to keep the lights on into the second half of 2016. The end of March brought yet another lengthy anonymous pump from a newly-created sockpuppet on Seeking Alpha, although this one didn't even take the time to invent a profile for itself. That should be a hint that the key is pump financing. The linchpin is likely phase II data for Prurisol for plaque psoriasis with topline data expected in May. This is a randomized placebo-controlled trial, so grab your popcorn. It will be interesting to see how management pulls out a victory in this must-win situation. If the answer is huge spin on mediocre data, better break out your short stick because the dilution will be coming hard and fast.

Meanwhile, if you haven't realized yet that it's impossible to develop three unpartnered clinical stage drugs simultaneously while spending only 3M/quarter, you need to go back to biotech scam school.

Recs

0
Member Avatar naughtyguy (61.38) Submitted: 3/28/2016 1:49:53 PM : Underperform Start Price: $1.87 CTIX Score: +2.93

Nothing in phase3 yet. Investors will get impatient and go elsewhere for quicker returns. The company will probably need to sell more stock to keep up with their spending.

Recs

0
Member Avatar EvanBuck (99.90) Submitted: 8/6/2015 7:08:07 PM : Underperform Start Price: $2.96 CTIX Score: +37.21

Another fraud company. http://seekingalpha.com/article/3406365-cellceutix-empty-office-unviable-science-misleading-disclosures-96-percent-downside

Recs

0
Member Avatar BooDog2 (< 20) Submitted: 5/6/2015 1:18:45 PM : Outperform Start Price: $2.42 CTIX Score: -23.13

$CTIX Setting up as a bounce play from long term support. Pending up list to NASDAQ CM. Quite the pipeline with expansion already planned for Kevetrin. Do your DD.

Recs

0
Member Avatar eyezie1 (< 20) Submitted: 4/9/2014 2:47:04 AM : Outperform Start Price: $1.57 CTIX Score: +6.03

Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.

Recs

0
Member Avatar adi101 (78.23) Submitted: 3/2/2014 7:45:11 AM : Outperform Start Price: $1.95 CTIX Score: -17.36

clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.

Recs

0
Member Avatar kmac28 (< 20) Submitted: 12/9/2013 6:49:02 AM : Outperform Start Price: $1.62 CTIX Score: -0.12

Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.

Recs

0
Member Avatar jed71 (99.85) Submitted: 9/12/2013 11:38:55 AM : Underperform Start Price: $1.97 CTIX Score: +28.61

Pump N Dump scam.

Results 1 - 9 of 9

Featured Broker Partners